Niacin/laropiprant [MK0524A] not approvable in US.

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1637, 2008-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefits of niacin/laropiprant combo come under question

Reactions Weekly, Vol. 1, Iss. 1434, 2013-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Niacin/laropiprant offers a lipid-altering experience

Inpharma, Vol. 1, Iss. 1604, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

By Perry Caroline M.

Drugs, Vol. 69, Iss. 12, 2009-08 ,pp. : 1665-1679

Adis International

Access to resources Recommend Favorite

Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

By Yadav Rahul France Michael Younis Naveed Hama Salam Ammori Basil J Kwok See Soran Handrean

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1345-1362

Informa Healthcare

Access to resources Recommend Favorite

A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin

By Yiu Kai-Hang Cheung Bernard MY Tse Hung-Fat

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 3, 2010-03 ,pp. : 437-449

Informa Healthcare

Access to resources Recommend Favorite